Dr. Nissar A. Darmani
My Social Links

Dr. Nissar A. Darmani

Associate Dean
Western University of Health Sciences, USA

Highest Degree
Ph.D. in Neuropharmacology from University of Wales, UK

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Pharmaceuticals
62%
Biochemistry
90%
Behavioural Neuroscience
75%
Neuropharmacology
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Zhong, W., A.J. Picca, A.S. Lee and N.A. Darmani, 2017. Ca2+ signaling and emesis: Recent progress and new perspectives. Autonomic Neurosci.: Basic Clin., 202: 18-27.
    CrossRef  |  Direct Link  |  
  2. Zhong, W. and N.A. Darmani, 2017. Intracellular vomit signals and cascades downstream of emetic receptors: Evidence from the least shrew (Cryptotis parva) model of vomiting. Remed Open Access, Vol. 2. .
    Direct Link  |  
  3. Darmani, N.A., S. Chebolu, W. Zhong, W.D. Kim, M. Narlesky, J. Adams and F. Dong, 2017. The anti-asthmatic drug pranlukast suppresses the delayed-phase vomiting and reverses intracellular indices of emesis evoked by cisplatin in the least shrew (Cryptotis parva). Eur. J. Pharmacol., 809: 20-31.
    CrossRef  |  Direct Link  |  
  4. Darmani, N.A., S. Chebolu and W. Zhong, 2017. Clinical potential of a new class of antiemetic for the prevention of chemotherapy-evoked acute- and delayed vomiting: Supportive evidence from the least shrew (Cryptotis parva) model of emesis. Austin Pharmacol. Pharmaceut., Vol. 2, No. 1. .
    Direct Link  |  
  5. Arodaki, F., W. Khamas, N. Darmani and M. Al-Tikriti, 2017. Histological characteristics of the tracheobronchial tree of the least shrew (Cryptotis parva). Anat. Histol. Embryol., 46: 405-409.
    CrossRef  |  Direct Link  |  
  6. Zhong, W., S. Chebolu and N.A. Darmani, 2016. Thapsigargin-induced activation of Ca2+-CaMKII-ERK in brainstem contributes to substance P release and induction of emesis in the least shrew. Neuropharmacology, 103: 195-210.
    CrossRef  |  Direct Link  |  
  7. Hutchinson, T.E., W. Zhong, S. Chebolu, S.M. Wilson and N.A. Darmani, 2015. L-type calcium channels contribute to 5-HT3-receptor-evoked CaMKIIα and ERK activation and induction of emesis in the least shrew (Cryptotis parva). Eur. J. Pharmacol., 755: 110-118.
    CrossRef  |  Direct Link  |  
  8. Darmani, N.A., W. Zhong, S. Chebolu and F. Mercadante, 2015. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation. Pharmacol. Biochem. Behav., 131: 104-111.
    CrossRef  |  Direct Link  |  
  9. Darmani, N.A. and W. Zhong, 2015. Role of calcium in vomiting: Revelations from the least shrew model of emesis. Gastro Open J., 1: 119-128.
    Direct Link  |  
  10. Zhong, W., T.E. Hutchinson, S. Chebolu and N.A. Darmani, 2014. Serotonin 5-HT3 receptor-mediated vomiting occurs via the activation of Ca2+/CaMKII-dependent ERK1/2 signaling in the least shrew (Cryptotis parva). PLoS ONE, Vol. 9. 10.1371/journal.pone.0104718.
    CrossRef  |  Direct Link  |  
  11. Zhong, W., S. Chebolu and N.A. Darmani, 2014. Broad-spectrum antiemetic efficacy of the L-type calcium channel blocker amlodipine in the least shrew (Cryptotis parva). Pharmacol. Biochem. Behav., 120: 124-132.
    CrossRef  |  Direct Link  |  
  12. Sharkey, K.A., N.A. Darmani and L.A. Parker, 2014. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur. J. Pharmacol., 722: 134-146.
    CrossRef  |  Direct Link  |  
  13. Darmani, N.A., W. Zhong, S. Chebolu, M. Vaezi and T. Alkam, 2014. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT3 receptor antagonist palonosetron in the least shrew (Cryptotis parva). Eur. J. Pharmacol., 722: 2-12.
    CrossRef  |  Direct Link  |  
  14. Darmani, N.A., S. Chebolu, W. Zhong, C. Trinh, B. McClanahan and R.S. Brar, 2014. Additive antiemetic efficacy of low-doses of the cannabinoid CB1/2 receptor agonist Δ9-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva). Eur. J. Pharmacol., 722: 147-155.
    CrossRef  |  Direct Link  |  
  15. Alkam, T., S. Chebolu and N.A. Darmani, 2014. Cyclophosphamide causes activation of Protein Kinase A (PKA) in the brainstem of vomiting least shrews (Cryptotis parva). Eur. J. Pharmacol., 722: 156-164.
    CrossRef  |  Direct Link  |  
  16. Darmani, N.A., D. Dey, S. Chebolu, B. Amos, R. Kandpal and T. Alkam, 2013. Cisplatin causes over-expression of tachykinin NK1 receptors and increases ERK1/2- and PKA‐ phosphorylation during peak immediate- and delayed-phase emesis in the least shrew (Cryptotis parva) brainstem. Eur. J. Pharmacol., 698: 161-169.
    CrossRef  |  
  17. Darmani, N.A., 2013. New vistas in the pathophysiology of vomiting. Family Med. Med. Sci. Res., Vol. 2. 10.4172/2327-4972.1000e105.
    CrossRef  |  
  18. Darmani, N.A. and S. Chebolu, 2013. The Role of Endocannabinoids and Arachidonic Acid Metabolites in Emesis. In: Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features, Murillo-Rodriguez, E., E.S. Onaive, N.A. Darmani and E. Wagner (Eds.). Chapter 2, Bentham Science Publishers, UAE., ISBN: 978-1-60805-125-0, pp: 25-59.
  19. Al-Tikriti, M.S., W. Khamas, S. Chebolu and N.A. Darmani, 2013. Histomorphology and immunohistochemistry of the lower esophageal sphincter of the least shrew (Cryptotis parva). Cells Tissues Org., 198: 390-397.
    CrossRef  |  Direct Link  |  
  20. Al-Tikriti, M.S., W. Khamas, S. Chebolu and N.A. Darmani, 2012. Distribition of Serotonin-immunoreactive chromaffin cells in the gastrointestinal tract of the least shrew (Cryptotis parva). Int. J. Morphol., 30: 916-923.
    Direct Link  |  
  21. Darmani, N.A., S. Chebolu, B. Amos and T. Alkam, 2011. Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK 1-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol. Biochem. Behav., 99: 573-579.
    CrossRef  |  Direct Link  |  
  22. Tiwari, V., N.A. Darmani, B.Y. Yue and D. Shukla, 2010. In vitro antiviral activity of neem (Azardirachta indica L.) bark extract against herpes simplex virus type-1 infection. Phytother. Res., 24: 1132-1140.
    CrossRef  |  PubMed  |  
  23. King, K.S., N.A. Darmani, M.S. Hughes, K.T. Adams and K. Pacak, 2010. Exercise-induced nausea and vomiting: Another sign and symptom of pheochromocytoma and paraganglioma. Endocrine, 37: 403-407.
    CrossRef  |  
  24. Hubbard, S., N.A. Darmani, G.R. Thrush, D. Dey and L. Burnham et al., 2010. Zebrafish-encoded 3-O-sulfotransferase-3 isoform mediates herpes simplex virus type 1 entry and spread. Zebrafish, 7: 181-187.
    CrossRef  |  
  25. Dey, D., J. Abad, A.P. Ray and N.A. Darmani, 2010. Differential temporal changes in brain and gut substance P mRNA expression throughout the Time-course of Cisplatin-induced vomiting in the least shrew (Cryptotis parva). Brain Res., 1310: 103-112.
    CrossRef  |  Direct Link  |  
  26. Darmani, N.A., 2010. Mechanisms of Broad-spectrum antiemetic efficacy of cannabinoids against Chemotherapy-induced acute and delayed vomiting. Pharmaceuticals, 3: 2930-2955.
    CrossRef  |  
  27. Darmani, N.A., 2010. Cannabinoid-induced hyperemesis: A conundrum-from clinical recognition to basic science mechanisms. Pharmaceuticals, 3: 2163-2177.
    CrossRef  |  
  28. Chebolu, S., Y. Wang, A.P. Ray and N.A. Darmani, 2010. Pranlukast prevents cysteinyl Leukotriene-induced emesis in the least shrew (Cryptotis parva). Eur. J. Pharmacol., 628: 195-201.
    CrossRef  |  Direct Link  |  
  29. Wang, Y., A.P. Ray, B.A. McClanahan and N.A. Darmani, 2009. The antiemetic interaction of Δ9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol. Biochem. Behav., 91: 367-373.
    CrossRef  |  Direct Link  |  
  30. Tiwari, V., N.A. Darmani, G.R. Thrush and D. Shukla, 2009. An unusual dependence of human herpesvirus-8 Glycoproteins-induced Cell-to-cell fusion on heparan sulfate. Biochem. Biophys. Res. Commun., 390: 382-387.
    CrossRef  |  Direct Link  |  
  31. Ray, A.P., S. Chebolu, J. Ramirez and N.A. Darmani, 2009. Ablation of least shrew central neurokinin NK₁ receptors reduces GR73632-induced vomiting. Behav. Neurosci., 123: 701-706.
    CrossRef  |  
  32. Ray, A.P., S. Chebolu and N.A. Darmani, 2009. Selective agonists induce emesis and Fos expression in the brainstem and and enteric nervous system of the least shrew (Cryptotis parva). Pharmacol. Biochem. Behav., 94: 211-218.
    CrossRef  |  
  33. Ray, A.P., L. Griggs and N.A. Darmani, 2009. Δ9-Tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of Cisplatin-induced emesis in the least shrew. Behav. Brain Res., 196: 30-36.
    CrossRef  |  Direct Link  |  
  34. Darmani, N.A., J.L. Crim, J.J. Janoyan, J. Abad and J. Ramirez, 2009. A Re-evaluation of the neurotransmitter basis of Chemotherapy-induced immediate and delayed vomiting: Evidence from the least shrew. Brain Res., 1248: 40-58.
    CrossRef  |  Direct Link  |  
  35. Darmani, N.A. and A.P. Ray, 2009. Evidence for a Re-evaluation of the neurochemical and anatomical bases of Chemotherapy-induced vomiting. Chem. Rev., 109: 3158-3199.
    CrossRef  |  Direct Link  |  
  36. Darmani, N.A., Y. Wang, J. Abad, A.P. Ray, G.R. Thrush and J. Ramirez, 2008. Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists. Brain Res., 1214: 58-72.
    CrossRef  |  Direct Link  |  
  37. Ray, A.P. and N.A. Darmani, 2007. A histologically derived stereotaxic atlas and substance P immunohistochemistry in the brain of the least shrew (Cryptotis parva) support its role as a model organism for behavioral and pharmacological research. Brain Res., 1156: 99-111.
    CrossRef  |  Direct Link  |  
  38. Degenhardt, B.F., N.A. Darmani, J.C. Johnson, L.C. Towns and D.C. Rhodes et al., 2007. Role of osteopathic manipulative treatment in altering pain biomarkers: A pilot study. J. Am. Osteopathic Associat., 107: 387-400.
    Direct Link  |  
  39. Darmani, N.A., J.J. Janoyan, J. Crim and J. Ramirez, 2007. Receptor mechanism and antiemetic activity of Structurally‐diverse cannabinoids against Radiation‐induced emesis in the least shrew. Eur. J. Pharmacol., 563: 187-196.
    CrossRef  |  Direct Link  |  
  40. Darmani, N.A., 2006. Methods Evaluating Endocannabinoids and Cannabinoid Effects on Gastrointestinal Functions. In: Marijuana and Cannabinoid Research: Methods and Protocols, Onaivi, E.S. (Ed.). Chapter 10, The Humana Press Inc., Totowa, New Jersey, USA., pp: 169-189.
  41. Mock, O.B., S.W. Casteel, N.A. Darmani, J.H. Shaddy, C. Besch-Williford and L.C. Towns, 2005. 1,3-dinitrobenzene toxicity in the least shrew, Cryptotis parva. Environ. Toxicol. Chem., 24: 2519-2525.
    CrossRef  |  
  42. Darmani, N.A., B.A. McClanahan, C. Trinh, S. Petrosino, M. Valenti and V. Di Marzo, 2005. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology, 49: 502-513.
    CrossRef  |  Direct Link  |  
  43. Darmani, N.A., A.A. Izzo, B. Degenhardt, M. Valenti and G. Scaglione et al., 2005. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available Pre-clinical data, and first human studies. Neuropharmacology, 48: 1154-1163.
    CrossRef  |  Direct Link  |  
  44. Darmani, N.A., 2005. Endocannabinoids and Gastrointestinal Function. In: Endocannabinoids: The Brain and Body's Marijuana and Beyond, Onaivi, E.S., T. Sugiura and V. DiMarzo (Eds.). CRC Press, New York, pp: 393-418.
  45. Darmani, N.A. and J.L. Crim, 2005. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D 2/D< sub>3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol. Biochem. Behav., 80: 35-44.
    CrossRef  |  Direct Link  |  
  46. Darmani, N.A. and J.C. Johnson, 2004. Central and peripheral mechanisms contribute to the antiemetic actions of Δ9-THC against 5-hydroxytryptophan-induced emesis. Eur. J. Pharmacol., 488: 201-212.
  47. Darmani, N.A., L.J. Sim-Selley, B.R. Martin, J.J. Janoyan, J.L. Crim, B. Parekh and C.S. Breivogel, 2003. Antiemetic and motor-depressive actions of CP55, 940: Cannabinoid CB1 receptor characterization, distribution and G-protein activation. Eur. J. Pharmacol., 459: 83-95.
    CrossRef  |  Direct Link  |  
  48. Darmani, N.A., J.J. Janoyan, N. Kumar and J.L. Crim, 2003. Behaviorally active doses of the CB1 receptor antagonist SR141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav., 75: 777-787.
  49. Janoyan, J., J. Crim and N.A. Darmani, 2002. Antagonism of SR 141716A-induced Head-twitch and Ear-scratch responses in mice by Δ9-THC and other cannabinoids. Pharmacol. Biochem. Behav., 71: 155-162.
  50. Darmani, N.A., 2002. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Δ9-Tetrahydrocannabinol and other cannnabinoids. J. Pharmacol. Exp. Ther., 300: 34-42.
    CrossRef  |  Direct Link  |  
  51. Darmani, N.A., 2002. Antiemetic Action of Δ9-Tetrahydrocannabinold and Synthetic Cannabinoids. In: Biology of Marijuana: From Gene to Behavior, Onaivi, E.S. (Ed.). Chapter 13, Taylor and Francis Books Ltd., London, UK., pp: 356-389.
  52. Tizabi, Y., L.T. Russell, M. Johnson and N.A. Darmani, 2001. Nicotine attenuates DOI-induced Head-twitch response in mice: Implications for tourette syndrome. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 25: 1445-1457.
    CrossRef  |  Direct Link  |  
  53. Mock, O.B., S.W. Casteel, N.A. Darmani, J.H. Shaddy, C. Besch-Williford and L.C. Towns, 2001. Anatomic and physiologic reference values in least shrews (Cryptotis parva). Compar. Med., 51: 534-537.
    Direct Link  |  
  54. Darmani, N.A., 2001. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur. J. Pharmacol., 430: 49-58.
    CrossRef  |  Direct Link  |  
  55. Darmani, N.A., 2001. Delta-9-tetrahydrocannabinol differentially suppresses Cisplatin-induced emesis and indices of motor function via cannabinoid CB 1 receptors in the least shrew. Pharmacol. Biochem. Behav., 69: 239-249.
    CrossRef  |  Direct Link  |  
  56. Darmani, N.A., 2001. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT 2A Receptor-mediated behaviors in mice. Pharmacol. Biochem. Behav., 68: 311-317.
    CrossRef  |  Direct Link  |  
  57. Darmani, N.A., 2001. Δ9-Tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology, 24: 198-203.
    CrossRef  |  
  58. Dukat, M., R. Young, N.N. Darmani, B. Ahmed and R.A. Glennon, 2000. The 5-HT3 agent N-(3-chlorophenyl) guanidine (MD-354) serves as a discriminative stimulus in rats and displays partial agonist character in a shrew emesis assay. Psychopharmacology, 150: 200-207.
    CrossRef  |  
  59. Darmani, N.A. and D.K. Pandya, 2000. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J. Neural Trans., 107: 931-945.
    CrossRef  |  
  60. Darmani, N.A. and B. Ahmad, 2000. Early postnatal cocaine exposure causes sequential, Dose-dependent, enduring but reversible supersensitivity in 5-HT 2A Receptor-mediated function during development in male mice. Neurotoxicol. Teratol., 22: 61-69.
    CrossRef  |  Direct Link  |